Pharmacokinetics of Hydroxychloroquine in Pregnancies with Rheumatic Diseases

Clinical Pharmacokinetics

Volumn 58, Issue 4, 2019, Pages 525-533

  Balevic, Stephen J ^a,b,d   Green, Thomas P ^c   Clowse, Megan E B ^b   Eudy, Amanda M ^b   Schanberg, Laura E ^a,b   Cohen Wolkowiez, Michael ^a,b  

^a DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^b DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c NORTHWESTERN UNIVERSITY   (United States)

^d DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CREATININE; HYDROXYCHLOROQUINE; ANTIRHEUMATIC AGENT;

ADULT; ALLOMETRY; AREA UNDER THE CURVE; ARTICLE; BAYES THEOREM; BODY MASS; COMPARTMENT MODEL; CONCENTRATION AT STEADY-STATE; CONNECTIVE TISSUE DISEASE; CREATININE BLOOD LEVEL; DRUG CLEARANCE; ELIMINATION RATE CONSTANT; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HISTOGRAM; HUMAN; JUVENILE RHEUMATOID ARTHRITIS; LIMIT OF QUANTITATION; MAJOR CLINICAL STUDY; PHARMACOKINETIC PARAMETERS; PHARMACOKINETICS; PREGNANCY; PRESCRIPTION; PRIMIGRAVIDA; PRIORITY JOURNAL; PUERPERIUM; RHEUMATIC DISEASE; TANDEM MASS SPECTROMETRY; VOLUME OF DISTRIBUTION; BIOLOGICAL MODEL; BLOOD; METABOLISM; YOUNG ADULT;

ADULT; ANTIRHEUMATIC AGENTS; FEMALE; HUMANS; HYDROXYCHLOROQUINE; MODELS, BIOLOGICAL; PREGNANCY; RHEUMATIC DISEASES; YOUNG ADULT;

EID: 85053867497     PISSN: 03125963     EISSN: 11791926     Source Type: Journal    
DOI: 10.1007/s40262-018-0712-z     Document Type: Article

References (27)

1. Clowse ME. Lupus activity in pregnancy. Rheum Dis Clin N Am. 2007;33:237–52.
2. Gotestam Skorpen C, Hoeltzenbein M, Tincani A, Fischer-Betz R, Elefant E, Chambers C, et al. The EULAR points to consider for use of antirheumatic drugs before pregnancy, and during pregnancy and lactation. Ann Rheum Dis. 2016;75:795–810.
3. Clowse ME, Magder L, Witter F, Petri M. Hydroxychloroquine in lupus pregnancy. Arthritis Rheum. 2006;54:3640–7.
4. Eudy AM, Siega-Riz AM, Engel SM, Franceschini N, Howard AG, Clowse MEB, et al. Effect of pregnancy on disease flares in patients with systemic lupus erythematosus. Ann Rheum Dis. 2018;77:855–60.
5. Fischer-Betz R, Specker C, Brinks R, Aringer M, Schneider M. Low risk of renal flares and negative outcomes in women with lupus nephritis conceiving after switching from mycophenolate mofetil to azathioprine. Rheumatology (Oxford). 2013;52:1070–6.
6. Ke AB, Rostami-Hodjegan A, Zhao P, Unadkat JD. Pharmacometrics in pregnancy: an unmet need. Annu Rev Pharmacol Toxicol. 2014;54:53–69.
7. Abduljalil K, Furness P, Johnson TN, Rostami-Hodjegan A, Soltani H. Anatomical, physiological and metabolic changes with gestational age during normal pregnancy: a database for parameters required in physiologically based pharmacokinetic modelling. Clin Pharmacokinet. 2012;51:365–96.
8. Rainsford KD, Parke AL, Clifford-Rashotte M, Kean WF. Therapy and pharmacological properties of hydroxychloroquine and chloroquine in treatment of systemic lupus erythematosus, rheumatoid arthritis and related diseases. Inflammopharmacology. 2015;23:231–69.
9. Browning DJ. Pharmacology of chloroquine and hydroxychloroquine. In: Hydroxychloroquine and chloroquine retinopathy. New York: Springer New York; 2014. pp. 35–63.
10. NMS Labs. Hydroxychloroquine test summary sheet. http://www.nmslabs.com/tests/Hydroxychloroquine–Serum-Plasma/2362SP. Accessed 6 Feb 2018.
11. Lim HS, Im JS, Cho JY, Bae KS, Klein TA, Yeom JS, et al. Pharmacokinetics of hydroxychloroquine and its clinical implications in chemoprophylaxis against malaria caused by Plasmodium vivax. Antimicrob Agents Chemother. 2009;53:1468–75.
12. Morita S, Takahashi T, Yoshida Y, Yokota N. Population pharmacokinetics of hydroxychloroquine in Japanese patients with cutaneous or systemic lupus erythematosus. Ther Drug Monit. 2016;38:259–67.
13. Costedoat-Chalumeau N, Amoura Z, Hulot JS, Aymard G, Leroux G, Marra D, et al. Very low blood hydroxychloroquine concentration as an objective marker of poor adherence to treatment of systemic lupus erythematosus. Ann Rheum Dis. 2007;66:821–4.
14. Costedoat-Chalumeau N, Le Guern V, Piette JC. Routine hydroxychloroquine blood concentration measurement in systemic lupus erythematosus reaches adulthood. J Rheumatol. 2015;42:1997–9.
15. Iudici M, Pantano I, Fasano S, Pierro L, Charlier B, Pingeon M, et al. Health status and concomitant prescription of immunosuppressants are risk factors for hydroxychloroquine non-adherence in systemic lupus patients with prolonged inactive disease. Lupus. 2018;27:265–72.
16. Carmichael SJ, Charles B, Tett SE. Population pharmacokinetics of hydroxychloroquine in patients with rheumatoid arthritis. Ther Drug Monit. 2003;25:671–81.
17. Tett SE, Cutler DJ, Day RO, Brown KF. A dose-ranging study of the pharmacokinetics of hydroxy-chloroquine following intravenous administration to healthy volunteers. Br J Clin Pharmacol. 1988;26:303–13.
18. Jallouli M, Galicier L, Zahr N, Aumaitre O, Frances C, Le Guern V, et al. Determinants of hydroxychloroquine blood concentration variations in systemic lupus erythematosus. Arthritis Rheumatol. 2015;67:2176–84.
19. Yeon Lee J, Lee J, Ki Kwok S, Hyeon JuJ, Su Park K, Park SH. Factors related to blood hydroxychloroquine concentration in patients with systemic lupus erythematosus. Arthritis Care Res (Hoboken). 2017;69:536–42.
20. Hebert MF, Zheng S, Hays K, Shen DD, Davis CL, Umans JG, et al. Interpreting tacrolimus concentrations during pregnancy and postpartum. Transplantation. 2013;95:908–15.
21. Costedoat-Chalumeau N, Houssiau F, Izmirly P, Le Guern V, Navarra S, Jolly M, et al. A prospective international study on adherence to treatment in 305 patients with flaring SLE: assessment by drug levels and self-administered questionnaires. Clin Pharmacol Ther. 2018;103(6):1074–82.
22. Durcan L, Clarke WA, Magder LS, Petri M. Hydroxychloroquine blood levels in systemic lupus erythematosus: clarifying dosing controversies and improving adherence. J Rheumatol. 2015;42:2092–7.
23. Costedoat-Chalumeau N, Amoura Z, Hulot JS, Hammoud HA, Aymard G, Cacoub P, et al. Low blood concentration of hydroxychloroquine is a marker for and predictor of disease exacerbations in patients with systemic lupus erythematosus. Arthritis Rheum. 2006;54:3284–90.
24. Tett SE, Cutler DJ, Beck C, Day RO. Concentration-effect relationship of hydroxychloroquine in patients with rheumatoid arthritis: a prospective, dose ranging study. J Rheumatol. 2000;27:1656–60.
25. Munster T, Gibbs JP, Shen D, Baethge BA, Botstein GR, Caldwell J, et al. Hydroxychloroquine concentration-response relationships in patients with rheumatoid arthritis. Arthritis Rheum. 2002;46:1460–9.
26. Lee JY, Vinayagamoorthy N, Han K, Kwok SK, Ju JH, Park KS, et al. Association of polymorphisms of cytochrome P450 2D6 with blood hydroxychloroquine levels in patients with systemic lupus erythematosus. Arthritis Rheumatol. 2016;68:184–90.
27. Shaw E, Kaczorowski J. Postpartum care: what’s new? Curr Opin Obstet Gynecol. 2007;19:561–7.